MiNK Therapeutics, Inc. (INKT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in MiNK Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

MiNK Therapeutics, Inc. (INKT) has returned -5.56% so far this year and 21.88% over the past 12 months.

Based on dividend-adjusted daily data since Oct 15, 2021, INKT's average daily return is +0.52%, while the average monthly return is -1.53%.

Historically, 30% of months were positive and 70% were negative. The best month was Jul 2025 with a return of +105.2%, while the worst month was Dec 2021 at -61.6%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 9 months.

On a daily basis, INKT closed higher 43% of trading days. The best single day was Jul 11, 2025 with a return of +730.1%, while the worst single day was May 1, 2023 at -39.1%.

MiNK Therapeutics, Inc. has an annualized alpha of 253.79%, beta of 0.50, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 18, 2021.

• This stock participated in 153.27% of S&P 500 Index downside but only -54.22% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.50 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INKT ranks 66 for risk / return — better than 66% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for MiNK Therapeutics, Inc. (INKT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the MiNK Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MiNK Therapeutics, Inc. was 97.69%, occurring on Dec 18, 2024. The portfolio has not yet recovered.

The current MiNK Therapeutics, Inc. drawdown is 94.74%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of MiNK Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how MiNK Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.